Ralliant (NYSE:RAL) Cut to Hold at Wall Street Zen

Wall Street Zen lowered shares of Ralliant (NYSE:RAL) from a buy rating to a hold rating in a research report released on Sunday morning.

Several other equities analysts have also commented on the stock. Citigroup increased their price objective on shares of Ralliant from $70.00 to $81.00 and gave the company a “buy” rating in a research report on Monday, July 13th. BMO Capital Markets began coverage on shares of Ralliant in a research report on Monday, July 20th. They set a “market perform” rating and a $78.00 target price on the stock. Zacks Research upgraded shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 30th. Morgan Stanley increased their price target on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a report on Tuesday, June 23rd. Finally, TD Cowen lifted their price target on Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Ralliant presently has a consensus rating of “Moderate Buy” and an average price target of $73.00.

Ralliant Stock Down 3.1%

NYSE RAL opened at $67.69 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The company has a market capitalization of $7.58 billion and a P/E ratio of -6.19. Ralliant has a one year low of $37.27 and a one year high of $75.41. The stock has a 50 day moving average price of $66.83 and a 200-day moving average price of $54.05.

Ralliant (NYSE:RAL) last posted its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The firm had revenue of $534.60 million during the quarter. Ralliant’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities analysts predict that Ralliant will post 2.64 EPS for the current fiscal year.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were given a $0.05 dividend. The ex-dividend date was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is currently -1.83%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Danske Bank A S purchased a new stake in shares of Ralliant in the fourth quarter valued at $25,000. V Square Quantitative Management LLC purchased a new position in shares of Ralliant during the 4th quarter worth about $26,000. Allworth Financial LP grew its holdings in Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares during the last quarter. Palisade Asset Management LLC bought a new position in Ralliant during the 3rd quarter valued at about $26,000. Finally, BOKF NA bought a new position in Ralliant during the 3rd quarter valued at about $29,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.